BACKGROUND:Postmenopausal conjugated equine estrogens (CEE) therapies increase the risk of cognitive impairment in women aged 65 years or older and are associated with smaller regional brain volumes; however, the link between these two phenomena has not been established. METHODS:Standardized magnetic resonance imaging was performed on 1,403 women, 1-4 years after they had participated in randomizedplacebo-controlled clinical trials of CEE-based therapies. Women included in this report were aged 65-80 years and free of dementia and mild cognitive impairment (MCI) when originally enrolled in the trials, which lasted an average of 4-6 years and were conducted at 14 academic U.S. medical centers. The associations that regional brain volumes and ischemic lesion volumes had with the development of cognitive impairment (i.e., dementia or MCI) were contrasted between treatment groups using analyses of covariance. RESULTS: Fifty-three women developed MCI or probable dementia during follow-up. Among women who had been prescribed CEE-based therapies, cognitive impairment was associated with relatively smaller hippocampal (p = .0002) and total brain volumes (p = .03). Qualitatively, these associations appeared to be independent of their level of pretreatment cognitive function. Among women who had been prescribed placebo, these relationships were not evident; instead, cognitive impairment was associated with greater ischemic lesion volume in the frontal lobe (p = .007) and overall (p = .02). CONCLUSION: A mechanism by which CEE-based postmenopausal hormone therapy induces cognitive impairment appears to be through increased brain atrophy.
RCT Entities:
BACKGROUND: Postmenopausal conjugated equine estrogens (CEE) therapies increase the risk of cognitive impairment in women aged 65 years or older and are associated with smaller regional brain volumes; however, the link between these two phenomena has not been established. METHODS: Standardized magnetic resonance imaging was performed on 1,403 women, 1-4 years after they had participated in randomized placebo-controlled clinical trials of CEE-based therapies. Women included in this report were aged 65-80 years and free of dementia and mild cognitive impairment (MCI) when originally enrolled in the trials, which lasted an average of 4-6 years and were conducted at 14 academic U.S. medical centers. The associations that regional brain volumes and ischemic lesion volumes had with the development of cognitive impairment (i.e., dementia or MCI) were contrasted between treatment groups using analyses of covariance. RESULTS: Fifty-three women developed MCI or probable dementia during follow-up. Among women who had been prescribed CEE-based therapies, cognitive impairment was associated with relatively smaller hippocampal (p = .0002) and total brain volumes (p = .03). Qualitatively, these associations appeared to be independent of their level of pretreatment cognitive function. Among women who had been prescribed placebo, these relationships were not evident; instead, cognitive impairment was associated with greater ischemic lesion volume in the frontal lobe (p = .007) and overall (p = .02). CONCLUSION: A mechanism by which CEE-based postmenopausal hormone therapy induces cognitive impairment appears to be through increased brain atrophy.
Authors: Irina Rozovsky; Saske Hoving; Christopher P Anderson; James O'Callaghan; Caleb E Finch Journal: Neurosci Lett Date: 2002-05-03 Impact factor: 3.046
Authors: Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende Journal: JAMA Date: 2003-05-28 Impact factor: 56.272
Authors: S M Resnick; M A Espeland; S A Jaramillo; C Hirsch; M L Stefanick; A M Murray; J Ockene; C Davatzikos Journal: Neurology Date: 2009-01-13 Impact factor: 9.910
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Sally A Shumaker; Claudine Legault; Lewis Kuller; Stephen R Rapp; Leon Thal; Dorothy S Lane; Howard Fillit; Marcia L Stefanick; Susan L Hendrix; Cora E Lewis; Kamal Masaki; Laura H Coker Journal: JAMA Date: 2004-06-23 Impact factor: 56.272
Authors: Pauline M Maki; Lorraine Dennerstein; Margaret Clark; Janet Guthrie; Pamela LaMontagne; Deanne Fornelli; Deborah Little; Victor W Henderson; Susan M Resnick Journal: Brain Res Date: 2010-11-13 Impact factor: 3.252
Authors: Mark A Espeland; Robert L Brunner; Patricia E Hogan; Stephen R Rapp; Laura H Coker; Claudine Legault; Iris Granek; Susan M Resnick Journal: J Am Geriatr Soc Date: 2010-07 Impact factor: 5.562
Authors: Joseph S Goveas; Mark A Espeland; Patricia Hogan; Vonetta Dotson; Sergey Tarima; Laura H Coker; Judith Ockene; Robert Brunner; Nancy F Woods; Sylvia Wassertheil-Smoller; Jane M Kotchen; Susan Resnick Journal: J Affect Disord Date: 2011-02-24 Impact factor: 4.839
Authors: Laura H Coker; Mark A Espeland; Patricia E Hogan; Susan M Resnick; R Nick Bryan; Jennifer G Robinson; Joseph S Goveas; Christos Davatzikos; Lewis H Kuller; Jeff D Williamson; Cheryl D Bushnell; Sally A Shumaker Journal: Neurology Date: 2014-01-02 Impact factor: 9.910
Authors: Nicole M Armstrong; Mark A Espeland; Jiu-Chiuan Chen; Kamal Masaki; Jean Wactawski-Wende; Wenjun Li; Margery L S Gass; Marcia L Stefanick; JoAnn E Manson; Jennifer A Deal; Stephen R Rapp; Frank R Lin; Susan M Resnick Journal: J Gerontol A Biol Sci Med Sci Date: 2020-02-14 Impact factor: 6.053
Authors: Mark A Espeland; Sally A Shumaker; Iris Leng; JoAnn E Manson; Candice M Brown; Erin S LeBlanc; Leslie Vaughan; Jennifer Robinson; Stephen R Rapp; Joseph S Goveas; Jean Wactawski-Wende; Marcia L Stefanick; Wenjun Li; Susan M Resnick Journal: JAMA Intern Med Date: 2013-08-12 Impact factor: 21.873
Authors: Joseph S Goveas; Stephen R Rapp; Patricia E Hogan; Ira Driscoll; Hilary A Tindle; J Carson Smith; Shelli R Kesler; Oleg Zaslavsky; Rebecca C Rossom; Judith K Ockene; Kristine Yaffe; JoAnn E Manson; Susan M Resnick; Mark A Espeland Journal: J Gerontol A Biol Sci Med Sci Date: 2016-03 Impact factor: 6.053
Authors: Mark A Espeland; Roberta Diaz Brinton; JoAnn E Manson; Kristine Yaffe; Christina Hugenschmidt; Leslie Vaughan; Suzanne Craft; Beatrice J Edwards; Ramon Casanova; Kamal Masaki; Susan M Resnick Journal: Neurology Date: 2015-07-10 Impact factor: 9.910